MARLBOROUGH, Mass., Oct. 1, 2018 /PRNewswire/ --
Hologic, Inc. (Nasdaq: HOLX), is the world leader in breast cancer screening technology and the maker of the Genius™ 3D Mammography™ exam, the only mammogram that is FDA-approved as superior to standard 2D mammography for routine breast cancer screening of women with dense breasts.2
Leading OB/GYN Dr. DaCarla Albright is joined by Grammy award-winning artist, breast cancer survivor and Genius exam spokesperson Sheryl Crow to share results from Hologic's recent survey, conducted online by The Harris Poll among over 1,000 U.S. women, designed to highlight the need for education about breast density and the impact it has on breast cancer screening and cancer detection.
Hologic survey findings include:
- 64 percent of U.S. women do not know that the density of a woman's breasts impacts her risk of developing breast cancer;
- More than two-thirds of U.S women (68 percent) do not know their breast density score; and
- Just 36 percent of women have discussed their breast density with a medical professional – this percentage is slightly higher among women ages 40+, at 43 percent.
- Knowing that having dense breasts increases a person's risk of developing breast cancer, 84% of women would be more likely to go to a facility with mammogram technology proven to be more accurate for women with dense breasts (compared to standard mammography if all things were equal)
The Genius™ 3D Mammography™ exam (also known as the Genius™ exam) is only available on a Hologic® 3D Mammography™ system. The Genius™ exam consists of a 2D and 3D™ image set, where the 2D image can be either an acquired 2D image or a 2D image generated from the 3D™ image set. There are more than 5,000 Hologic 3D Mammography™ systems in use across the United States, so women have convenient access to the Genius™ exam. To learn more about the Genius™ exam, visit http://Genius3DNearMe.com.
1 HOLOGIC survey, conducted online by The Harris Poll August 14-16, 2018 among 1,155 U.S. women ages 18+, among whom 710 were ages 40+. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated. For complete survey methodology, including weighting variables and subgroup sample sizes, please contact Jane Mazur.
2 FDA submissions P080003, P080003/S001, P080003/S004, P080003/S005.
SOURCE Hologic, Inc.